Evangelia Petsalaki: New Systems Biology Approach Identifies Biomarkers in Thrombotic APS
Evangelia Petsalaki, Director of Oncology Data Science Innovation at GSK and Visiting Group Leader at EMBL-EBI, shared on LinkedIn about a recent article she and her colleagues co-authored, published in medRxiv, adding:
”We’re pleased to share our latest preprint on thrombotic primary antiphospholipid syndrome (APS).
In this study, we integrated plasma proteomics, whole-blood transcriptomics, machine learning and network-based analysis to investigate the molecular programmes associated with high-risk disease.
Across multiple complementary analyses, we found evidence for a complement- and interferon-associated thromboinflammatory programme linked to increasing antiphospholipid antibody burden and recurrent thrombosis. Integrating the data using multi-omics factor analysis and network propagation also connected circulating protein signatures to intracellular signalling pathways, providing a systems-level view of disease biology.
Among the findings, Complement Factor D (CFD) emerged as a candidate biomarker associated with recurrent thrombosis, although this will require validation in independent cohorts.
This work was a fantastic collaboration between colleagues at EMBL-EBI, the National and Kapodistrian University of Athens, and the Biomedical Sciences Research Center ‘Alexander Fleming’.
Many thanks to everyone involved, especially Srijith Sasikumar and Maria Tektonidou as well as our coauthors Michail Baltsiotis, Kleio-Maria Verrou, Georgia Rouni, Martina Samiotaki, Petros Sfikakis and the rest of the team.”
Title: Multi-omics and network propagation reveal latent innate immune programmes stratifying high-risk thrombotic primary antiphospholipid syndrome
Authors: Srijith Sasikumar, Michail Baltsiotis, Kleio-Maria Verrou, Georgia Rouni, Petros P. Sfikakis, Martina Samiotaki, Evangelia Petsalaki, Maria G. Tektonidou
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 11, 2026, 22:40Bahram Alamdary Badlou: Platelets as First Responders in Hemostasis, Immunity, and Inflammation
-
Oct 11, 2026, 22:22Vipin Singh: New Publication on Hippo-YAP Signaling and Platelet Activation
-
Oct 11, 2026, 22:21Trygve Berge: New AFNOR Paper on AF-related Stroke in Norway
-
Oct 11, 2026, 22:09Omar Alomari: Our New Publication on Apixaban vs Rivaroxaban for VTE
-
Oct 11, 2026, 21:22Shayan Roshan: Happy to Share Two Research Milestones in Trauma Care and Pancreatic Cancer
-
Oct 11, 2026, 21:16Chokri Ben Lamine: Anemia in Myelofibrosis – Multiple Mechanisms, Limited Responses
-
Oct 11, 2026, 21:03Carmela Walker: Supporting Warriors Living With SCD Through Dental Care and Advocacy
-
Oct 11, 2026, 21:00Rishdha Roshad: Intraoperative Cell Salvage – Turning Blood Loss into an Opportunity for Recovery
-
Oct 11, 2026, 20:59Anthony R. Sloan: Honored to Share Our Work at the 20th Midwest Platelet Conference